West Midlands researchers to study weight-loss medications as treatment for common cause of female infertility

Researchers in the West Midlands have been given a £60,000 grant to study the affects of weight-loss drugs on women with Polycystic Ovarian Syndrom (PCOS).

Polycystic Ovary Syndrome (PCOS) is a common hormone condition that can affect how the ovaries work, causing irregular periods, acne, extra hair growth, or trouble getting pregnant. It can also make it harder for the body to use insulin properly and may increase the risk of weight gain and other health problems.

Some women are prescribed Metformin, a diabetes drug, off-label to manage the insulin resistance symptoms. However, researchers are now looking at the recent advancements in weight-loss drugs as other possible treatment options for women with the condition that is the most common cause of female infertility.

Dr. Shagaf Bakour, a gynecologist and director of medical education at Aston Medical School, won an NHS research grant to study the possibility in a project co-developed with Dr. Hoda Harb, a consultant obstetrician and gynecologist at Sandwell and West Birmingham NHS Trust who was a co-applicant on the funded grant.

Medicines like Mounjaro and Ozempic, which are used for weight loss and controlling blood sugar, might also help women with Polycystic Ovary Syndrome. This is important because women with PCOS are more likely to have weight gain, insulin resistance, diabetes, and heart problems.

Researchers at Aston University and Sandwell and West Birmingham NHS Trust have will look at existing research to see what is already known about treating the condition with GLP-1 medications and what still needs to be studied.

If approved, they will use real-world data from fertility clinics, GP records, and weight-management services to see how well these medicines work for women with PCOS in everyday life.

Speaking about the study, Dr. Bakour said: "The aim is to give women with PCOS evidence-informed, clearer treatment options and more consistent care. The project hopes to show whether these medicines can improve both general health and fertility health, while also helping local services develop clearer care pathways.

“Currently, care can vary, and women do not always get the same advice or treatment options. The research could lead to earlier support, better long-term health, and more joined-up care for a condition that affects many women but is still often overlooked.”

Professor Elizabeth Hughes, director of research and development at Sandwell and West Birmingham NHS Trust added: "In the longer term, the work is intended to produce published evidence, support further external funding, and help prevent longer-term health problems linked to PCOS."

“The effects of PCOS, which include infertility, are very emotive subjects and so we are delighted to support Dr Shagaf Bakour and Dr Hoda Harb with their research into possible treatments.

“We should be doing all we can within research and development to advance healthcare for women and to better help future generations with this condition."